Speakers

Keynote Speakers:

Kenneth R. Pelowski, Founder & Managing Partner, Pinnacle Ventures
Ken founded Pinnacle while working at Redpoint Ventures. Prior to Redpoint, Ken founded and was Chairman of the Board of Currenex, which was acquired by State Street for $560 million. Prior to Currenex, Ken was Chief Operating Officer, Chief Financial Officer and a Board Director of GetThere (a Brentwood Venture Capital/USVP portfolio company), where he led its IPO as well as its $750 million acquisition by Sabre. Prior to joining GetThere, Ken was Executive Vice President and Chief Financial Officer of Preview Travel (a Kleiner Perkins portfolio company) which acquired and changed its name to Travelocity. Ken led Preview’s IPO. Before joining Preview Travel, Ken was a Corporate Vice President and Executive Committee Member at General Instruments and at Quantum Corporation where he was responsible for corporate strategy and business development. Previously, he held senior management positions in sales and marketing at Sun Microsystems and Intel. He currently is a board member on several privately held companies and nonprofit organizations. He received a BSE in electrical engineering and an MBA from the University of Michigan.

Alan G. Walton, Ph.D., D.Sc., Senior General Partner, Oxford Bioscience Partners
Alan Walton joined Oxford as a general partner in 1987. With offices in Massachusetts, Connecticut and California, the life sciences venture capital firm provides equity financing and management assistance to advanced-stage startups and later-stage commercially oriented organizations. The English-born Walton immigrated to the U.S. at age 24 and taught at Indiana University, Harvard Medical School and Case Western Reserve University, where he met and later became a science advisor to Governor and then President Jimmy Carter. After leaving academia in 1981, Walton founded University Genetics, one of the first biotechnology companies, and began advising venture capital firms in the biotech field, eventually transitioning to his partnership at Oxford. By 2007, the firm had more than $1 billion under management. A widely published scientific author and patent holder, as well as an aerobatic and jet aircraft pilot, Walton is one of the founders of Virgin Galactic, which is planning to rocket into space in 2009, and the founder and president of the National Committee on Bioscience Innovation, which supports the public advancement of biomedical inventions.

Panelists:

Ananth Ananthasubramaniam, Manager Technology Investments, DTE Energy, Inc.
Ananth leads the technology investment group and serves as vice president for DTE Energy Ventures. Ananth joined the group in 1995, and has led several DTE Energy investments. Ananth is a director in Solena and Pentadyne Power Inc. and board observer in Real Energy and Cell Tech. Prior to DTE Energy, Ananth was a management consultant with Booz Allen and Hamilton and EDS. Ananth has a B.S. in Mechanical Engineering from IIT Madras, and MS in Industrial Engineering from University of Florida and an MBA from the Kellogg School of Management at Northwestern University.

Matt Alves, Vice President, Strategic Business Development, Stryker Instruments
Mr. Alves graduated from the Massachusetts Institute of Technology in 1980 with a degree in Mechanical Engineering. From1980 to 1982, Mr. Alves worked for Corning Glass Works as a Manufacturing Engineer and a Process Engineer, MedicalDivision. After obtaining a degree in General Management from Harvard Business School in 1984, he joined Stryker as assistantto the President. He has held the following positions at Stryker: Director of Manufacturing Engineering, R&D Director, Marketing Manager, Director of Marketing, Vice President of Marketing, and then, Vice President of Strategic Development, hiscurrent position. Throughout his career, he has seen the company grow from $87 million to $2.2 billion. Mr. Alves currently coor-dinates acquisitions for both the Leibinger and Instruments Divisions and is also in charge of Customer Service.

Andrew R. Basile, Jr., Chairman, Young Basile Hanlon MacFarland Helmholdt
Andrew Basile is a shareholder in the firm's Palo Alto office. Prior to joining Young Basile, Mr. Basile was a partner in the Bay Area offices of Cooley Godward, where he managed the 18-attorney information technology practice in that firm's San Francisco office. Mr. Basile concentrates his practice on intellectual property and technology transactions relating to software, hardware, electronics, semiconductors, nanotechnology and the Internet. He handles a wide variety of technology-related commercial transactions including strategic alliances and joint ventures, inbound and outbound licensing of software, hardware and other technology, IT procurement and outsourcing, distribution agreements, and development and systems integration projects. An experienced patent attorney, he also advises clients with respect to the prosecution, acquisition, disposition and commercialization of all forms of intellectual property.

Joshua Bilenker, M.D., Associate, Aisling Capital
Dr. Bilenker serves as an Associate of Aisling Capital. Previously, Dr. Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. Dr. Bilenker received his M.D. from The Johns Hopkins School of Medicine. He received his A.B. from Princeton, awarded summa cum laude in English.

Jeff Bocan, Managing Director, Beringea
Mr. Bocan is the head of the Los Angeles office and is responsible for investment sourcing, analysis, deal execution and portfolio management. He focuses on the media and entertainment sector and has expertise in content creation, internet advertising, licensing, TV production and publishing. Mr. Bocan serves as a board director for the following Beringea portfolio companies: Shout! Factory, Porchlight Entertainment, GetBack Media, Steak Media, Eagle Rock Entertainment, Imagestate and Starbridge Media. Prior to joining Beringea, Mr. Bocan was an Associate at early- stage technology VC firm Saffron Hill Ventures in London. He has also worked in marketing roles for BMW of North America and beverage company Honest Tea. During the Clinton administration, he worked on Capitol Hill as a Lobbyist for the Sierra Club, focusing on pollution issues. Mr. Bocan graduated with a BA in Government and Sociology from the University of Notre Dame, graduating magma cum laude and Phi Beta Kappa; and received an MBA with high honors from the University of Virginia.

Hugh Douglas Camitta, Partner, Pepper Hamilton LLP
Hugh Douglas Camitta, a partner in the Commercial Practice group of the Detroit office of Pepper Hamilton LLP, has a practice that concentrates on venture capital, private investment funds, mergers and acquisitions, and securities transactions. Mr. Camitta has assisted in the formation and operation of venture capital and other investment funds and their managers, including funds licensed as small business investment companies by the U.S. Small Business Administration. He has negotiated and documented financings in seed capital, development stage and public companies, representing issuers and investors. Mr. Camitta counsels venture capital entities, corporations, financial institutions and institutional investors in leveraged buyouts and workouts of investments. His representation of institutional investors includes documentation and counseling on a variety of debt and equity investments. His general corporate clients include high technology private corporations which produce software, environmental and automotive industry related products. Mr. Camitta has worked on matters involving protection and licensing of intellectual property.

Mary Campbell, Managing Director & Founder, EDF Ventures
Mary Campbell is a Managing Director and Founder of EDF Ventures. She has been an active investor both in healthcare and technology companies for 20 years. Currently, Mary is on the Board of Directors of several healthcare and technology companies: Quadraspec and Handylab (clinical diagnostics); Lycera (pharmaceuticals); ValenTx (medical devices); IntelePeer, RockeTalk, Sircon, and Vontoo (technology). She also leads EDF investments in Cerenis (pharmaceuticals) and Greenplum (technology). Mary is also President of the Michigan Venture Capital Association, the State's premier public policy advocate for the venture capital industry. She is active with The Stephen M. Ross School of Business at the University of Michigan and currently serves as an advisor to the Zell Lurie Institute for Entrepreneurial Studies as well as its student-run venture activity, the Wolverine Venture Fund. She is an advisor to the University of Michigan's Life Science Institute and is a member of the Steering Committee for the Michigan Strategic Economic Investment and Commercialization Board, a Statewide initiative to foster research and commercialization. Mary received her MBA from the University of Michigan; her MA in Special Education from Fairfield University; and her BA in English from the University of Michigan.

Alison de Bord, Director, Alta Partners
Alison is a Director at Alta Partners, a life sciences venture capital firm based in San Francisco. Her primary investment focus at Alta is on medical technology and biopharmaceuticals. She serves on the board of directors for Aegerion Pharmaceuticals, Insulet Corporation, Prolacta Bioscience, Sierra Surgical Technologies, and SurgRx. Prior investments include Esperion Therapeutics and Kerberos Proximal Solutions. Alison joined Alta Partners as an Associate in 2001. Prior to Alta, she was a Senior Associate in Robertson Stephens’ Life Sciences Investment Banking Group with primary responsibilities for the execution of corporate finance transactions including IPOs, follow-on equity and convertible preferred offerings. Previously, she was an Associate in Robertson Stephens’ Equity Research Group where she focused on growth medical technology companies. She began her career in the business development group at Geron, a biotechnology company. Alison earned a Master of Business Administration from Columbia Business School and a Bachelor of Arts in History from Colgate University.

Thomas J. Dougherty, President & CEO, Monolith Engines Inc.; former Director, Advanced Battery and Hybrid
Systems, Johnson Controls
Thomas Dougherty retired In January from Johnson Controls Inc after 37 years as Director of Advanced Battery and Hybrid Systems. He started in Engineering Product Design and Development, Electrical Vehicle battery development, and served as Manager of the Quality Control Battery Test Labs and then served as Manager of Engineering of the Keefe Battery Plant for seven years which included product, process and factory engineering, and also served as the plant QC Manager. He then moved to Product Manager in Marketing, followed by Manager of New Product Development. Tom has 46 issued US patents in electronics, computer software, battery design, alternators, and systems engineering. His most recent patent is on a new hydrogen burning internal combustion engine. He has also written numerous papers for MIT, NEMA, IEEE, SAE and he is a current member of SAE and BCI. Tom owns his own business, Monolith Engines Inc., and is building a new patented internal combustion engine that is about half the size of existing engines and designed to use compressed gas and Hydrogen. He earned his BS in Chemistry and Mathematics from the University of Wisconsin – Oshkosh, followed by 19 years of study at the Milwaukee School of Engineering, Waukesha Technical Collage, Keller Business School and University of Wisconsin – Milwaukee. He has studied in electronics, electrical engineering, computers and business management.

Dave Fachetti, Managing Director, Globespan Capital Partners
As a Managing Director of Globespan, Dave sources new investment opportunities, evaluates and negotiates investments, and serves on the boards of portfolio companies. Based in Boston, he focuses on investments in Software,Internet/Infrastructure and Cleantech companies. He also leads Globespan's CIO Advisory Board, which he helped to establish. Dave brings deep operating expertise in fast-growth environments, a strategic market view, and an intense commitment to help the firm's entrepreneurs achieve success in the technology marketplace. Dave serves on the boards of  Expressor Software, Fortisphere, Luidia, and Q1 Labs. He serves as a Board Observer for  Applied Identity, Instill and Openpages. Dave previously served on the board of Cloakware (acquired by Irdeto), Ingrian Networks (acquired by SafeNet), and Reflectent (acquired by Citrix). Prior to Globespan, Dave was a Principal of JAFCO Ventures, where he focused on enterprise software opportunities.

Jose Fernandez, Managing Director & General Counsel, StepStone LLC
Prior to founding StepStone, Mr. Fernandez was a Managing Director of PCG and a member of PCG’s Management Committee and Investment Committee. Mr. Fernandez served as Senior Vice President/General Counsel and Chief Compliance Officer of PCG before his promotion to Managing Director. During his years at PCG Mr. Fernandez created separate account structures and specialized fund of funds for clean energy technology and international investments. He also drafted and helped manage direct investment funds and co-investment funds. Mr. Fernandez negotiated investments on behalf of PCG clients totaling more than $8 billion in capital commitments. Mr. Fernandez was also responsible for establishing entities and opening offices in Washington, D.C., New York City and Geneva, Switzerland. Before joining PCG, Mr. Fernandez was an associate with the Corporate Department of the Los Angeles office of Latham and Watkins LLP. Mr. Fernandez was a member of Latham’s Private Equity/Investment Fund Group with a practice focused on joint ventures and the structuring, negotiation and operation of pooled investment vehicles such as private equity funds, hedge funds, funds of funds, buyout funds, real estate funds and ‘special situation’ funds. He also has experience advising such investment vehicles with respect to the acquisition and disposition of preferred stock and convertible debt securities. Before joining Latham he was an associate with the New York office of Curtis, Mallet-Prevost, Colt & Mosle, LLP. Mr. Fernandez is a graduate of Stanford Law School and received his undergraduate degree from the University of Michigan, Ann Arbor. Mr. Fernandez is licensed to practice law in California and New York.

Annette Finsterbusch, Partner, Applied Ventures LLC
Annette Finsterbusch is a partner for Applied Ventures in the Corporate Business Development group of Applied Materials since 2004, responsible for identifying, recommending and managing venture capital investments. She is also a Kauffman Fellow. Prior to joining Applied Materials, Ms. Finsterbusch was the CEO at MindShadow.com, a technology spin-out of DaimlerChrysler's Research and Technology Center. Prior to that position, Ms. Finsterbusch was an investment manager for DaimlerChrysler Venture Capital since 2001, responsible for enterprise software investments. Ms. Finsterbusch also had previously worked for Applied Materials, leading its business development efforts in Russia, Belarus and Armenia from 1996 through 2000, chartering the company's first office in Moscow. Ms. Finsterbusch's philanthropic directorships include seats on both the Board of Directors for the Junior League of San Jose and the Exception Women Executives of San Jose State University. Ms. Finsterbusch received a Bachelor of Science in economics and geology from the University of Houston and a Master's in Business Administration in Strategy and Finance from San Jose State University, where she was honored with the Graduate of the Last Decade (GOLD) Award in 2004.

Maurice Gunderson, Senior Partner, CMEA Ventures
Maurice Gunderson joined CMEA Ventures in October 2006 to focus on investments in new and innovative energy sources and technologies. Maurice is a specialist in thermodynamics and energy technologies. Throughout Maurice's career, he has been instrumental in the development of cryogenic equipment, energy systems, turbo-machinery, and computer-based control systems for process plants and pipeline systems. Previously, Maurice co-founded Nth Power, a venture capital firm specializing in investments emerging from the global restructuring of the energy industry. Prior to founding Nth Power, Maurice spent more than 20 years developing profitable products and launched five successful companies. Maurice also has served on the board of directors of many energy technology companies, including Capstone Turbine, CellTech Power, Clean Air Power, Electronic Power Conditioning, H2Gen Innovations, Metallic Power, NanoGram, NEOPhotonics, Pentech Solution, Pentadyne Power, and STM Power. He currently serves on the board of CMEA Ventures portfolio company Superprotonic. Maurice has an MBA from Stanford University as well as MS and BA degrees in Mechanical Engineering from Oregon State University. He is also a member of ASME, SAE, ASHRAE, AIAA and AEE, and a patent holder, Registered Professional Engineer, and pilot.

Vinay Gupta, Founder & CEO, Janeeva, Inc.
Vinay is the founder and CEO of Janeeva Inc . Prior to launching Janeeva, Vinay was Entrepreneur in Residence with Ardesta LLC, a pioneer in investing in "small tech" MEMS companies. Through Ardesta, Vinay served as president of three venture backed companies: Sensicore, Discera and Translume. In 1996, Vinay co-founded BlueGill Technologies, an Internet infra-structure company that specializes in Internet billing software. BlueGill was sold to CheckFree Corporation in 2000 for $250 million. Vinay has held positions as Managing Director-Asia Pacific and General Manager-India for Cabletron Systems, as well as Manager of Global Operations at NCR and Zenith Electronics. Vinay continues to serve on the board of directors for Translume.

Michael J. Jandernoa, Co-founder, Bridge Street Partners, LLC
Michael J. Jandernoa is a co-founder of Bridge Street Partners, LLC, a private equity fund located in Grand Rapids, Michigan. He is former chairman and current board member of Perrigo Company, the nation’s largest manufacturer and marketer of store brand over-the-counter drug and nutritional products. Jandernoa is a graduate of the University of Michigan and a certified public accountant, having worked at BDO Seidman for seven years prior to joining Perrigo in 1979. Hired by Perrigo as vice president of finance, Jandernoa was promoted to executive vice president of sales and finance in 1981, appointed president in 1983, and became chief executive officer in 1986, a position he held until May 2000. He served as chairman of the board from November 1991 through August 2003. In addition to his service on Perrigo’s board of directors, Jandernoa also serves on the board of directors of Old Kent Financial Corporation, Grand Valley University Foundation, the University of Michigan Business School Visiting Committee, the NACDS Associate Member Advisory Board, and the Technology Tri-Corridor. Jandernoa is a member of the Young President’s Organization, Michigan Business Roundtable, and other corporate advisory boards. He also serves/chairs on numerous religious and community boards and committees.

Koleman Karleski, Managing Director, Chrysalis Ventures
Koleman joined Chrysalis in 1997 and is currently a Managing Director. His focus is on healthcare services and technology, and business services. At Chrysalis, Koleman has worked with Aperture Credentialing (sold to a subsidiary of UnitedHealth Group), Manorhouse Assisted Living (sold to LifeTrust Assisted Living), Primis (sold to LandAmerica Financial Group), and TechRepublic (sold to Gartner Group, Inc.). He currently serves on the Board of AfterBOT, Chronicity, ConnectivHealth, HealthMedia, and MedServe. He also spearheads Chrysalis’ marketing and fundraising efforts. Prior to Chrysalis, Koleman worked for Providian Corporation's Capital Management business unit where he focused on strategic planning and business development. A native of Pittsburgh, Koleman earned a BSE from Princeton University where he concentrated on operations research and financial engineering. In his civic capacity, Koleman volunteers for Big Brothers Big Sisters of Kentuckiana, and is President of the Princeton Alumni Association of Louisville.

Nina Kjellson, Partner, InterWest Partners
Nina Kjellson is a Partner with InterWest Partners, a diversified venture capital firm with more than $2B under management. Nina focuses primarily on investments in the biopharmaceutical area. She is a board member of Alvine Pharmaceuticals, Sequel Pharmaceuticals, a spin-off from NovaCardia, Inc. (acquired by Merck; Nasdaq: MRK), Primera Biosystems and Trius Therapeutics. Additionally, she is an observer on the boards of AkaRx/Drais, Devax, Inc., Kanisa Pharmaceuticals, MacuSight, Inc., and Nereus Pharmaceuticals. Kjellson also played a primary role in InterWest's investment in Aspreva Pharmaceuticals (Nasdaq: ASPV, acquired by Galenica Canada, a wholly owned subsidiary of Galenica Group of Switzerland).

Jeffrey LaBine, Principal, Miller Canfield
Jeffrey L. LaBine is a principal and a member of the Corporate and Securities and Venture and Technology Practice Groups. His corporate, finance, venture capital and mergers and acquisitions practice includes private and public securities offerings, venture capital financing, mergers and acquisitions, financing, shareholder relations, public company representation, and general corporate representation of start-up and established companies through all phases of their life cycles, from entity formations to exits. He received his law degree, magna cum laude, from Wayne State University, and his B.B.A., with high honors, from Detroit College of Business. Prior to joining Miller Canfield he was in the Child and Family Abuse Bureau of the Wayne County Office of the Prosecuting Attorney and served as a noncommissioned officer in the United States Air Force from 1983-1988. Mr. LaBine is a member of the American Bar Association and the State Bar of Michigan. He has published several articles regarding venture capital finance, mergers and acquisitions, securities laws, and fraudulent transfer issues. He has also been a speaker on mergers and acquisitions, venture capital and start-up issues to a wide variety of audiences for organizations such as Ann Arbor SPARK and the Samuel Zell & Robert H. Lurie Institute at the University of Michigan Ross School of Business.

John Lovitt, Investor, Executive Advisor & Retired SVP Field Operations, Rational Software (now IBM)
John Lovitt is an investor, board member, and advisor to technology startup companies, with a focus on issues related to technology adoption. John was a senior executive with Rational Software from 1986 to 2003 with roles including VP Worldwide Services, and Senior VP Worldwide Field Operations. Rational software (now part of IBM) helps organizations by improving their software development capability. John played a key role in shaping Rational's team oriented approach to achieving customer results by accelerating adoption of tools and best practices. Prior to joining Rational, he was with Hewlett-Packard for 13 years, and McDonnell Douglas for 5 years. John earned a Master of Science degree in computer science from Missouri University of Science and Technology (formerly UMR). He also holds a Bachelor of Science degree in aeronautical engineering from Wichita State University. John and his wife Diane live in the San Francisco Bay area, where they are active with Habitat for Humanity. They have taught leadership and entrepreneurship at summer programs for international high school students in Eastern Europe and China.

Jim Matheson, General Partner, Flagship Ventures
Jim joined Flagship Ventures in 2000 and focuses on new ventures in the IT and special technology (e.g. nano-technology, specialty materials, and energy) arenas. He brings to this task 20 years of technology and leadership experience across a variety of organizations and roles designing, engineering and deploying sophisticated technology platforms. Jim formerly served as a Navy fighter pilot including duties flying combat missions from aircraft carriers, and as a TOPGUN Instructor. He also gained broad experience in emerging weapons system design, testing and procurement, and was deeply involved in many of the military’s IT modernization initiatives.

Jim earned an MBA from The Harvard Business School, and a Bachelor of Science (with honors) from the United States Naval Academy and he continues to serve as a Commander in the US Naval Reserves. He serves on the boards of Flagship portfolio companies Avidimer Therapeutics, e-Dialog, Genstruct, Mascoma Energy Corporation, Novomer, Tira Wireless and Trusted Network Technologies, and is Chairman of the Board of Ze-gen. He was previously a director of Yantra (acquired by Sterling Commerce / SBC) and Flamenco Networks (acquired by SOA Software). Jim is on the Board of New York-based hedge fund Black Horse Capital, Common Impact (a non-profit providing IT services to other non-profits), and the Center for Women & Enterprise, and is actively involved in numerous entrepreneurial and venture capital organizations including the MIT Enterprise Forum, The Deshpande Center, and The Service Academy Business Network .

Michael Melnick, Ph.D., Principal, CMEA Ventures
Michael Melnick joined CMEA as Principal in 2008. Prior to CMEA, Michael was Chief Commercial Officer and Executive VP of Operations at Assay Designs from 2006 to 2007; co-founder and Vice President of Business and Corporate Development at Cell Signaling Technology from 1999 to 2006; and staff scientist at New England Biolabs from 1995 to 1999. Michael has a PhD in Genetics from Harvard University, a BS degree with honors from Stanford University, and an MS degree in Biological Sciences from Stanford University.

Robert J. More, Partner, Domain Associates, LLC
Mr. More joined Domain Associates as a Kauffman Fellow in 1996, and he became a Partner in 2000. Present board memberships include Achaogen, Acureon Pharmaceuticals, Apnex Medical, Carticept Medical, Evoke Pharma, Glaukos, Lipothera, Novalar Pharmaceuticals, OmniSonics Medical Technologies and TargetRx. Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), Onux Medical (acquired by C.R. Bard), NovaCardia (acquired by Merck), and Esprit Pharma (acquired by Allergan). Mr. More was also responsible for Domain’s investment in IntraLase (acquired by Advanced Medical Optics, Inc.). Additionally, Mr. More served as a Founding board member for Kauffman Fellows Program and serves as an Advisory board member for Montagu Newhall Associates, Okapi Ventures, The Medical Industry Group of the NVCA and The Sulpizio Family Cardiovascular Center. From 1997-1998, Mr. More served as the Chief Operating Officer of Small Molecule Therapeutics, a Domain portfolio company subsequently purchased by Morphochem AG. From 1992 to 1995, Mr. More was with Pharmacia Biotech in sales. Prior to joining Pharmacia, Mr. More held a research position at Somatogen, a company developing a recombinant blood substitute that was subsequently bought by Baxter. While attending business school, Mr. More worked with MedVest, an early-stage venture group in Washington, D.C. He earned a BA from Middlebury College and an MBA from the Darden School of Business Administration at the University of Virginia

Rand Mueller, CEO & Co-founder, Guidepoint Systems
Rand Mueller is a pioneer in the vehicle security and convenience industry and the visionary who conceived Guidepoint™. A college dropout, he quit engineering school at University of Michigan in 1967 to start the first of several automotive electronics businesses. Three decades later, he's still creating black boxes that make life safe, secure and convenient for drivers. Along the way, he founded and ran Code-Alarm, Inc., a public company that engineered some of the best-known vehicle security/convenience brands - including Code-Alarm® and Chapman® - and that built products for GM, Ford, Chrysler, Toyota, Nissan, Honda and just about every other automaker on the planet. In 1988, he developed Intercept, a vehicle tracking and recovery system based on cellular phones and LORAN, a radio-navigation system that preceded the global positioning satellite (GPS) system. "We were a decade early," Mueller says. In 1999, the convergence of the Web, wireless networks and mobile electronics got his entrepreneurial juices flowing again. He stepped aside as chief executive officer of Code-Alarm in 2000 to become the Company's "chief entrepreneurial officer" and spearhead the development of its telematics solution - which is sold today as Guidepoint™.

Jon Norris, Managing Director, SVB Capital
Jon Norris is a managing director with SVB Capital's Private Equity Group, specializing in life sciences. Norris has more than seven years of banking experience focused on working with life science companies and venture capital firms. In his current role, Norris is responsible for strengthening relationships with select venture capital firms by leveraging SVB's platform of strategic business units, including investment and commercial banking, as well as global and analytical services. Prior to joining SVB Capital, Norris was a founding member and senior vice president of Square 1 Bank, an early stage technology bank, where he was an account officer responsible for sourcing deals and managing regional and national venture capital relationships. Norris also served more than six years at Imperial Bank (subsequently acquired by Comerica Bank), most recently as senior vice president and group manager of the Northern California Life Science Practice. Prior to banking, Norris was a practicing litigation attorney, specializing in employment defense and toxic tort litigation. Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.

Douglas E. Onsi, Venture Partner, HealthCare Ventures
Doug Onsi is a Venture Partner of HealthCare Ventures. Prior to joining HealthCare Ventures in 2007, he served as Vice President, Campath Product Operations & Oncology Portfolio Management and as Vice President, Business Development at Genzyme Corporation. Before joining Genzyme, Mr. Onsi was Chief Financial Officer and Vice President, Business Development of TolerRx, Inc., a company in which HealthCare Ventures was the lead investor. Prior to TolerRx, he held a senior business development position at LeukoSite, Inc., another HealthCare Ventures portfolio company, which was merged with Millennium Pharmaceuticals, Inc. He has also practiced corporate law at Bingham Dana LLP. Mr. Onsi received his J.D. degree from University of Michigan Law School and B.S. degree in biology from Cornell University.

Douglas Parks, Vice President of New Market Development, Michigan Economic Development Corporation
Doug Parks is Vice President of New Market Development for the Michigan Economic Development Corporation (MEDC) with specific focus on the alternative energy sector. He leads a broad-based team comprised of experts in biofuels, wind, solar, advanced energy storage, carbon sequestration, and water technology, who are dedicated to continue to increase the economy of Michigan while leveraging the State’s significant strengths in this sector. Prior to joining the corporation, Doug Parks was a vice president at Valassis Communications, heading a division that developed print, software, and website solutions for travel industry organizations. Doug began his career at MEDC as a division director for Travel Michigan, the state's tourism promotion and marketing organization, where he was responsible for technology initiatives, as well as overseeing the state's thirteen welcome centers. He subsequently served as their deputy director, dealing with program development and budget management, and later became vice president of e-MEDC, overseeing implementation of the corporation's technology for 24/7 delivery of services to customers. Doug has also served as MEDC’s senior vice president of administration, managing budget, finance, contracts and grants, office services, and human resources, information technology, web development, telecommunications, and customer relationship management; and directed the efforts of the organization’s research team. Doug is a retired U.S. Army Intelligence Officer and a graduate of Lake Superior State University.

David N. Parsigian, Partner, Honigman Miller Schwartz and Cohn LLP
David N. Parsigian is the Managing Partner of the Ann Arbor office of the law firm of Honigman Miller Schwartz and Cohn LLP where he specializes in venture capital financing and representation of technology-based companies. He has extensive experience in advising technology businesses with respect to locating sources of capital and structuring financings ranging from seed capital to initial public offerings. His legal expertise includes general corporate, finance, mergers and acquisitions, strategic alliances and technology licensing. Mr. Parsigian was recognized as one of The Best Lawyers in America in the Corporate Law Section of the 2008 and 2007 editions of that publication and by Chambers USA America’s Leading Lawyers for 2007 and 2006, as a top lawyer in the Corporate/Mergers and Acquisitions field in Michigan. Mr. Parsigian is a lecturer on matters relating to private equity finance and venture capital at the Ross School of Business at the University of Michigan, Michigan State University, Wayne State University and Walsh College. He is a founder and a former member of the Executive Committee of Great Lakes Entrepreneur’s Quest (a business plan competition for the State of Michigan); Executive Committee Member of Ann Arbor SPARK, an organization designed to enhance the entrepreneurial community in the Ann Arbor Area; a former board chair of both the Ann Arbor Area Chamber of Commerce and the Washtenaw Community College Foundation.. He received his law degree, with honors, from the University of Texas, and a B.S.M.E (mechanical engineering), magna cum laude, from the University of Michigan.

Robert D. Payne III, In-State Investment Specialist, Credit Suisse
Mr. Payne joined the Customized Fund Investment Group in August 2006 to manage Michigan Operations related to the Venture Michigan Fund and 21st Century Jobs Fund. Previously he was a Principal with Hamilton Lane Advisors where he was actively involved in the firm's private equity fund and co-investment efforts. Prior to that he was a Senior Managing Director with Comerica Capital Advisors where he managed a private equity portfolio consisting of over 120 funds and 25 direct investments. Mr. Payne received his MBA from the University of Chicago Graduate School of Business and his A.B. in Economics from Dartmouth College.

Tim Petersen, Managing Director, Arboretum Ventures
Tim Petersen specializes in investments in medical device, equipment, and healthcare service companies, leveraging his broad business background working in and with entrepreneurial firms. He focuses on 510(k) medical technology companies and healthcare service firms in orthopedics, critical care and other clinical areas. Tim currently serves on the board of directors for KFx Medical, Advanced ICU Care, HealthMedia, and Accuri Cytometers.

Tim's entire career has focused on creating, growing, and financing entrepreneurial companies. Before joining Arboretum in 2002, Tim was the Managing Director of the Zell Lurie Institute for Entrepreneurial Studies at the University of Michigan, leading the creation, execution, and rapid growth of the Institute's programs. He also directed the Wolverine Venture Fund (WVF), the Institute's venture capital fund that includes the active participation of Michigan's MBA students. During his four year tenure as the Director of the WVF, the Fund invested in a number of early-stage healthcare and technology companies, including IntraLase (acquired by American Medical Optics in 2007 for $800 million) and HandyLab. Previously, Tim spent nine years at Industrial Economics, Inc., becoming a member of the firm's senior management team in 1991. Industrial Economics, founded in the early 1980's in Cambridge, MA, is a leader in the fields of natural resource economics and environmental science. Earlier in his career, Tim was a manager in the investment banking practice at Plante & Moran.

Tim currently sits on the Michigan Universities Commercialization Initiative (MUCI) advisory board, which oversees the distribution of pre-seed grants to promising life science technologies within Michigan universities. He is also an advisory board member of the Biogenerator ( St. Louis, MO) and the Wolverine Venture Fund. Tim earned a BA in Economics from Williams College, an MS in Economics from the University of Wisconsin-Madison, and an MBA from the Ross School of Business at the University of Michigan.

Winslow Sargeant, Managing Director, Venture Investors LLC
Venture Investors is an early stage venture capital firm based in Madison, Wisconsin with an office in Ann Arbor, Michigan. From 2001 to 2005, Winslow was the program manager for the Small Business Innovations Research (SBIR) program Electronics topic in Industrial Innovation, a new office in the National Science Foundation’s (NSF) Engineering Directorate. From 1997 to 2000, Winslow cofounded Aanetcom, a startup company with seed funding from Cisco systems. On March 3, 2000, Aanetcom was acquired by PMC-Sierra. Prior to Aanetcom, Winslow held engineering positions at Lucent, AT&T Bell Labs, and IBM.

Winslow is a Kauffman Fellow (Class 11) and serves as a Director of the University of Wisconsin Foundation and a Trustee for the Wisconsin Alumni Research Foundation (WARF). He also serves on Purdue Discovery Research Board of Visitors. He received the inaugural 2002 Wisconsin Distinguished Young Alumni Award and was the 2003 Outstanding Engineering Alumni Awardee from Northeastern University. He holds a B.S. (Northeastern 1986), M.S. (Iowa State 1988), and Ph.D. (Wisconsin 1995), all in Electrical Engineering. Winslow currently serves on the Boards of CleanMake and Silatronix.

David R. Sarns, Managing Director, 360 Advisors, LLC
Mr. Sarns is the Managing Director of 360 Advisors L.L.C., a private investment and advisory firm which offers its services to emerging companies. He has over 25 years of experience in leading global organizations in the investment and securities field. Previously he served as Chief Operating Officer and Managing Director of Rockefeller & Co, a New York global asset management and financial advisory firm. He has also held a variety of senior management positions; including Managing Director and Chief Administrative Officer at SG Cowen Securities Corp. Mr. Sarns holds a MBA from University of Michigan and a BBA from Michigan State University.

Knut A. Simonsen, Senior Vice President, DTE Energy Resources; President, DTE Energy Ventures
Mr. Simonsen provides leadership in strategy, M&A and new business growth for DTE Energy, including supporting its utility and non-utility businesses. Furthermore, Simonsen is responsible for DTE Energy Ventures – DTE’s clean energy technology investment arm. Key areas of contribution to DTE’s growth include: developed entry strategy and responsible for initial build-out of DTE’s unconventional gas exploration and production business. Sold one of two businesses (Antrim shale in Michigan) in 2007 for $1.3 billion, continue to build Barnett Shale position in Texas; and defined gas storage and pipeline strategy for DTE, with follow-on acquisition of Duke’s share in the Vector Pipeline. Simonsen joined DTE Energy from McKinsey & Company’s Dallas, Texas office. At McKinsey, he was a management consultant specializing in the energy industry serving leading firms among gas and electric utilities and major oil companies. Areas of primary focus were merger and acquisitions, growth and restructuring strategies, wholesale trading, and performance management. Prior to McKinsey, Simonsen worked in Texaco’s Alternative Energy division based in New York. As a Project Manager at Texaco, Simonsen led power development teams in North America, Europe and Latin America. Alternative energy efforts focused on clean coal and waste gasification. Waste recycling/reuse efforts included plastics, tires, sewage sludge and auto fluff. Previously, Simonsen was an Assistant Treasurer in the New York based Project Finance group of Den Norske Bank, with responsibility for project finance primarily for wind, wood, and gas fired power projects. Simonsen earned an MBA from Columbia University in New York with concentration in Finance, and a bachelor of science degree in Petroleum Engineering from Texas A&M University.

Colin South, Ph.D., President & Chief Strategy Officer, Mascoma, Inc.
Dr. South has held leading technology and management-focused positions for companies in engineering, genetics and marketing arenas. He has over ten years of bioprocess design, construction and operation experience in the biotech industry acquired while with BioMetics Consulting. He was the former CEO of ViaLactia Biosciences, a gene discovery and commercialization company and was Fonterra Co-operative Group’s General Manager of Health and Nutrition in Auckland, New Zealand. Dr. South received a bachelor’s degree in Chemical Engineering from the University of Canterbury, Christchurch, New Zealand and both an ME in Engineering Management and a Ph.D. in Bioprocess Engineering from Dartmouth College.

Jeanne M. Sullivan, General Partner, StarVest Partners, L.P.
Jeanne Sullivan has had an email address since 1980! She has 17 years of private equity experience and has spent 27 years in the technology sector encompassing both extensive operating and investing experience with technology companies. Jeanne is a co-founder and General Partner of StarVest Partners, L.P. a New York City based venture capital firm with over $300 million under management. The firm invests in technology-enabled business services companies. As a General Partner of StarVest Partners and previously with Olivetti Ventures, Ms. Sullivan has served on the boards of many technology company boards. Ms. Sullivan has extensive experience creating “go to market” plans for expansion stage companies. Her expertise also includes strategy, a keen understanding of the technology landscape and industry trends. She is a graduate of the University of Illinois and Creighton University Law School. Ms. Sullivan is a sought-after industry speaker on the subject of investing in and building technology companies and serves as an adjunct professor of marketing at the graduate level. Her credentials also include: lousy golfer, baseball and sports addict, and oldest of eight kids where she learned the most about managing people and getting results.

Immanuel Thangaraj, Managing Director, Essex Woodlands Health Ventures
Mr. Thangaraj has 15 years of experience in operations and venture capital. Mr. Thangaraj began his venture career at ARCH Venture Partners ("AVP"), a leading venture capital firm with over $1 billion under management, which makes early stage technology and healthcare investments. In his initial tenure at AVP, he managed one of its portfolio companies, a medical information company, until its sale to a large hospital supplies company. In 1995, Mr. Thangaraj left AVP to run a telecommunications company until its sale to a public company. Mr. Thangaraj joined Essex Woodlands in 1997. He currently serves on the Board of Directors of CBR Systems, Acura Pharmaceuticals (formerly Halsey Pharmaceuticals), Clear Vascular, Proteus, Medlogics, and Sound ID. He is also responsible for Essex Woodland’s investment in Microport, China Stem Cell and Novacept (sold to Cytyc). Mr. Thangaraj holds a Bachelor of Arts and a Masters in Business Administration from the University of Chicago.

Phillip D. Torrence, Principal, Miller Canfield
Phillip D. Torrence, born Chicago, Illinois, May 28, 1974. Preparatory education, Hope College (B.A., 1996), legal education, University of Utah College of Law (J.D. 1999). Mr. Torrence is a Senior Principal who practices in the areas of general business and high-technology ventures. His corporate, finance, securities and venture capital practice includes private and public securities offerings, public company representation, mergers and acquisitions, financing, venture capital financing, executive compensation planning, corporate restructuring, going-private transactions, various regulatory and compliance matters, entity formation, shareholder relations, and other corporate matters, with a particular emphasis on medical device and life science companies as well as banks and bank holding companies. He regularly represents issuers and investors in life science companies in connection with transactions involving intellectual property or product rights, such as collaboration, development, manufacture supply and distribution agreements, technology acquisitions, university licenses, and the formation of joint ventures and other types of strategic alliances. Mr. Torrence is a member of the American Bar Association, Sate Bar of Michigan, Kalamazoo County Bar Association, Kalamazoo County Chamber of Commerce, Kalamazoo Institute of the Arts, and serves as an adjunct advisor to the Kalamazoo Bank consortium. He has published several articles regarding mergers and acquisitions and venture capital finance.